Sermorelin vs Tesamorelin: Key Differences in 2026
Published November 21, 2026
Sermorelin vs tesamorelin at a glance
| Sermorelin | Tesamorelin | |
|---|---|---|
| What it is | The first 29 amino acids of growth hormone-releasing hormone (GHRH) | A modified, full-length GHRH analog |
| FDA status today | No approved product on the market; compounded only | Approved as Egrifta WR |
| First US approval | 1997 (Geref), discontinued 2008 | 2010 |
| Approved use | Was: growth hormone deficiency in children with growth failure | Excess abdominal fat in adults with HIV and lipodystrophy |
| Label dose | None in force | 1.28 mg under the skin once a day |
| Largest trials | 19 adults for 16 weeks; 11 men for 6 weeks | Two trials, 806 adults, 26 weeks |
| Belly fat result | Not measured in the adult studies | Visceral fat down 14% to 18% at 26 weeks (placebo: up 2% and down 2%) |
| Effect on IGF-1 | Up in the 16-week study; unchanged in the 6-week study | Up by about 107 ng/mL |
| Banned in sport | Yes (WADA S2) | Yes (WADA S2) |
How they work
Your brain makes growth hormone-releasing hormone, a 44-amino-acid signal that tells the pituitary gland to release growth hormone. Growth hormone then raises IGF-1, the growth factor behind many of its effects.
Sermorelin is the first 29 amino acids of that signal, the part that activates the receptor. Tesamorelin is the full 44-amino-acid sequence with a chemical group added to slow its breakdown.
Both work through the pituitary, so the body's own feedback loop stays involved. That differs from injecting growth hormone itself.
What tesamorelin's trials showed
The Egrifta WR label reports two 26-week trials in adults with HIV and excess abdominal fat. Both used the older 2 mg formulation.
- Study 1: visceral fat fell 18% on tesamorelin (273 patients) and rose 2% on placebo (137 patients).
- Study 2: visceral fat fell 14% on tesamorelin (270 patients) and fell 2% on placebo (126 patients).
- IGF-1 rose by 107 to 108 ng/mL on tesamorelin.
The label sets limits on that result. Egrifta WR "is not indicated for weight loss management as it has a weight neutral effect," and its long-term cardiovascular safety has not been established.
What sermorelin's studies showed
Two 1997 studies carry most of the adult evidence.
- 16 weeks, 19 adults aged 55 to 71 (Khorram and colleagues, Journal of Clinical Endocrinology and Metabolism). Participants injected 10 mcg/kg of a close sermorelin analog each night. Nighttime growth hormone and IGF-1 rose. Skin thickness increased in men and women. Lean body mass, insulin sensitivity, well-being and libido improved in men only. The one side effect reported was a temporary rise in blood lipids.
- 6 weeks, 11 men aged 64 to 76 (Vittone and colleagues, Metabolism). Participants injected 2 mg each night. Growth hormone release rose. IGF-1, weight, muscle mass and fat mass did not change. Two of six strength measures improved.
Neither study measured visceral fat. Neither is large enough to settle what sermorelin does for adults.
Side effects and warnings
Tesamorelin's label gives the clearest picture for this drug class. In the 26-week trials:
- Injection-site reactions: 17% on tesamorelin, 6% on placebo
- Joint pain: 13% vs 11%
- Swelling in the limbs: 6% vs 2%
- Muscle pain: 6% vs 2%
The label warns about higher IGF-1, fluid retention, glucose intolerance or diabetes, and increased risk of neoplasms. It is contraindicated in active cancer, pregnancy, and pituitary disorders from surgery, tumor, radiation or trauma.
Compounded sermorelin has no current label. It raises growth hormone through the same receptor, so ask your prescriber how these cautions apply to you.
Access and cost
Tesamorelin is a brand-name prescription drug supplied as a kit of four vials for 28 days. Its approved use is narrow.
Sermorelin comes from compounding pharmacies with a prescription. FDA determined in March 2013 that Geref was not withdrawn for reasons of safety or effectiveness. Compounded sermorelin is not FDA-approved.
As of November 2026, Ozari Health lists compounded sermorelin at $159 a month, or $447 billed every three months, after a licensed provider's review. Ozari does not offer tesamorelin.
Which one fits
- You have HIV-associated lipodystrophy with excess abdominal fat: tesamorelin is the approved treatment. Talk with your HIV care team.
- You are asking about growth hormone support for recovery, sleep or body composition: neither drug is approved for that. Sermorelin is available by prescription from compounding pharmacies, and the supporting studies are small.
- You compete in tested sport: both are prohibited at all times.
Frequently Asked Questions
Is tesamorelin stronger than sermorelin?
No trial has compared them head to head. Tesamorelin has stronger evidence: two 26-week trials in 806 adults and an FDA approval. Sermorelin's adult studies enrolled 19 and 11 people.
Is sermorelin FDA-approved?
Not today. FDA approved Geref (sermorelin) on September 26, 1997 for growth hormone deficiency in children. The manufacturer discontinued it in 2008, and FDA withdrew the approval effective June 18, 2009. Sermorelin is now available only as a compounded medication, which is not FDA-approved.
Does tesamorelin cause weight loss?
Its label states it has a weight-neutral effect and is not indicated for weight loss. The trials showed a drop in visceral abdominal fat in adults with HIV and lipodystrophy.
Can I take sermorelin and tesamorelin together?
Both act on the same receptor, and no published trial has tested the combination. A prescriber would choose one.
How is each one taken?
Both are injected under the skin. Egrifta WR is 1.28 mg once a day. The adult sermorelin studies used a nightly injection, and the prescriber sets the dose.
Are sermorelin and tesamorelin banned in sports?
Yes. The World Anti-Doping Agency's 2026 Prohibited List names both under S2, growth hormone-releasing hormone and its analogues.
Sources
- Egrifta WR (tesamorelin) prescribing information, DailyMed
- Federal Register, March 4, 2013: Determination that Geref (sermorelin acetate) was not withdrawn for reasons of safety or effectiveness
- Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of a GHRH-(1-29) analog in age-advanced men and women. J Clin Endocrinol Metab, 1997
- Vittone J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism, 1997
- World Anti-Doping Agency: The Prohibited List, 2026
- Ozari Health: Sermorelin
This article is for informational purposes only and does not constitute medical advice. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. Clinical trial results for FDA-approved products should not be extrapolated as guaranteed outcomes for compounded medications. Individual results vary. Always consult a licensed healthcare provider before starting any prescription medication. Ozari Health is a telehealth platform that connects patients with licensed, independent healthcare providers.
Related Articles
BPC-157 Capsules vs Injection: What the Evidence Shows
No human trial compares oral and injected BPC-157. See what the 2026 HHS policy allows, the extra rule for capsules, and how prescribers choose a form.
Read more →treatmentBPC-157 Dosage: What Studies Used and Who Sets the Dose
No human trial has set a BPC-157 dose. See what the three small human studies used, where the 200 to 500 mcg figure comes from, and the 2026 HHS policy.
Read more →treatmentSemaglutide and Heart Health: The Trial That Changed What These Drugs Are For
The SELECT trial found semaglutide cut heart attack, stroke, and cardiovascular death by 20% in adults without diabetes — reshaping who these drugs are for.
Read more →